Articles From: Immunomedics Constructs New Humanized Antibody for B-Cell Mediated Cancer and Autoimmune Diseases to Impax Laboratories and TOLMAR, Inc. Announce Final FDA Approval for Generic Solaraze® Gel (Diclofenac Sodium-3%)


2013/7/16
MORRIS PLAINS, N.J., July 16, 2013 (GLOBE NEWSWIRE) -- Immunomedics , Inc. (Nasdaq:IMMU) ,a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported the issuance of U.S. Patent 8,486,395 with expiration on August 2, 2024.
Sign-up for Immunomedics Constructs New Humanized Antibody for B-Cell Mediated Cancer and Autoimmune Diseases investment picks
MORRIS PLAINS, N.J., Oct.
Sign-up for Immunomedics Develops Dendritic-Cell Vaccine Technology for Lymphomas and Leukemias investment picks
2014/2/26
MORRIS PLAINS, N.J., Feb.
Sign-up for Immunomedics Extends Patent Life on Therapeutic Antibodies investment picks
2014/2/4
MORRIS PLAINS, N.J., Feb.
Sign-up for Immunomedics Ranks 4th in the Patent Board Biotechnology Industry Scorecard investment picks
-- Partial Responses in Colorectal, Triple-Negative Breast, and Small-Cell-Lung Cancers --
Sign-up for Immunomedics Reports Multiple Objective Responses in Solid Cancers With IMMU-132 investment picks
2014/4/8
-- Preclinical Studies Presented at 2014 Annual Meeting of the American Association for Cancer Research (AACR) -- SAN DIEGO, April 8, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported results from preclinical studies on the Company's two investigational SN-38-containing antibody drug conjugates (ADCs), IMMU-130 and IMMU-132, that demonstrated a high therapeutic index for both agents.
Sign-up for Immunomedics Reports Preclinical Results on SN-38 Antibody-Drug Conjugates as a Potential Novel Platform for Treating Cancer investment picks
-- Subcutaneous Injections of Low-Dose Veltuzumab Produced High Objective Response Rate as a Single Agent --
Sign-up for Immunomedics Reports Promising Activity With Veltuzumab in Relapsed Immune Thrombocytopenia investment picks
2014/4/7
SAN DIEGO, April 7, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported the results from 3 Phase I trials with IMMU-130, the Company's investigational anti-CEACAM5 antibody conjugated to the irinotecan-metabolite, SN-38.
Sign-up for Immunomedics Reports Results From Three Phase I Trials With IMMU-130 in Metastatic Colorectal Cancer investment picks
AMSTERDAM, Netherlands, Sept.
Sign-up for Immunomedics Reports Updated Results of Labetuzumab-SN-38 in Metastatic Colorectal Cancer investment picks
2014/2/26
MORRIS PLAINS, N.J., Feb.
Sign-up for Immunomedics to Present at Cowen and Company 34th Annual Health Care Conference investment picks
2013/12/3
MORRIS PLAINS, N.J., Dec.
Sign-up for Immunomedics to Present at Oppenheimer 24th Annual Healthcare Conference investment picks
2013/9/4
MORRIS PLAINS, N.J., Sept.
Sign-up for Immunomedics to Present at Stifel Healthcare Conference 2013 investment picks
2014/3/31
MORRIS PLAINS, N.J., March 31, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that four posters will be presented at the 2014 Annual Meeting of the American Association for Cancer Research to be held in San Diego, CA, from April 5 – 9, 2014.
Sign-up for Immunomedics to Provide Clinical Trial Updates on Solid-Tumor Antibody-Drug Conjugates at Cancer Conference investment picks
2014/4/10
MORRIS PLAINS, N.J., April 10, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) , a biopharmaceutical company focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that Dr.
Sign-up for Immunomedics to Ring Opening Bell and Host R&D Day at the NASDAQ Stock Market investment picks
2014/2/21
NEW YORK , Feb.
Sign-up for Imogen Dillon Hatcher Joins S&P Capital IQ as Chief Commercial Officer investment picks
2014/2/11
SEATTLE , Feb.
Sign-up for Imogo Developing New Mobile Virtual Payment Platform for RFID Smartphones investment picks
2014/1/28
SEATTLE , Jan.
Sign-up for Imogo Enhances Secure Mobile email Platform, ZAOffice investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0890311001&sourceType=1 http://media3.marketwire.com/logos/20130802-imogo200.jpg SEATTLE, WASHINGTON --
Sign-up for Imogo Implements Competitive Mobile First Strategy investment picks
2014/1/9
Secure Mobile Bitcoin Payment Platform Under Development SEATTLE , Jan.
Sign-up for Imogo Joins Bitcoin Community investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0891506001&sourceType=1 SEATTLE, WASHINGTON --
Sign-up for Imogo Mobile Technologies Corp., SideBuy Technologies Inc. Sign MOU investment picks
2014/2/18
SEATTLE , Feb.
Sign-up for IMOGO Set to Debut iPad Mobile Office, Premier Mobile Project Management & Team Collaboration System investment picks
2014/1/30
SEATTLE , Jan.
Sign-up for Imogo Testing New Bitcoin Mobile Platform investment picks
2014/2/17
NEW YORK, Feb.
Sign-up for Impact of Corporate Action of Vodafone Group Plc on NASDAQ OMX Indexes investment picks
2013/11/15
By Razak Musah Baba LONDON--Impala Platinum Holdings Ltd.
Sign-up for Impala Platinum Appoints Nelson Ndlala Head of Rustenburg Operations investment picks
JOHANNESBURG--Impala Platinum Holdings (IMP.JO), the world's second-largest platinum producer, reported an increase in net profit for the first half of the year but said a costly strike continues to hit output.
Sign-up for Impala Platinum First Half Profit Up, But Strike Bites investment picks
By Ian Walker Impala Platinum Holdings Ltd.
Sign-up for Impala Platinum Talks With Union Fail investment picks
2014/1/23
By Ian Walker LONDON--Impala Platinum Holdings Ltd.
Sign-up for Impala Platinum to Lose 2,800 oz Platinum a Day During Strikes investment picks
Impax Laboratories, Inc.(NASDAQ:IPXL) and DURECT Corporation (Nasdaq:DRRX) announced today that they have entered into an agreement granting Impax the exclusive worldwide rights to develop and commercialize ELADUR ® , DURECT’s investigational transdermal bupivacaine patch for the treatment of pain associated with post-herpetic neuralgia (PHN). Under the terms of the agreement, Impax will pay DURECT an upfront fee of $2 million, with possible additional payments of up to $61 million upon the achievement of predefined development and commercialization milestones.
Sign-up for Impax and DURECT Sign a $63 Million Agreement to Develop and Commercialize DURECT’s ELADUR® Pain Patch investment picks
Impax Laboratories, Inc. (NASDAQ: IPXL) and TOLMAR, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of TOLMAR’s Abbreviated New Drug Application (ANDA) for its generic version of Solaraze® Gel (diclofenac sodium-3%). TOLMAR was the first company to file a substantially complete ANDA containing a Paragraph IV certification, and Impax’s generics division, Global Pharmaceuticals, intends to commercialize this first-to-file product shortly.
Sign-up for Impax Laboratories and TOLMAR, Inc. Announce Final FDA Approval for Generic Solaraze® Gel (Diclofenac Sodium-3%) investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Immunomedics Constructs New Humanized Antibody for B-Cell Mediated Cancer and Autoimmune Diseases to Impax Laboratories and TOLMAR, Inc. Announce Final FDA Approval for Generic Solaraze® Gel (Diclofenac Sodium-3%)
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity